Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 14 years
- Director since
- 2023
14 years of board service in total across 4 boards, counting each seat separately. Longest: Eledon Pharmaceuticals Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Travere Therapeutics Inc. May 19, 202697.9%
-
Travere Therapeutics Inc. May 15, 202598.8%
-
Travere Therapeutics Inc. May 8, 202495.5%
-
Travere Therapeutics Inc. May 17, 202393.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 18, 2026 | Travere Therapeutics Inc. | Option exercise | +5,000 | $17.44 | $87,200 |
| Aug 18, 2026 | Travere Therapeutics Inc. | Open-market sale | −4,100 | $63.27 | $259,407 |
| Aug 18, 2026 | Travere Therapeutics Inc. | Open-market sale | −900 | $63.86 | $57,474 |
| Aug 17, 2026 | Travere Therapeutics Inc. | Option exercise | +5,000 | $17.44 | $87,200 |
| Aug 17, 2026 | Travere Therapeutics Inc. | Open-market sale | −1,900 | $62.53 | $118,807 |
| Aug 17, 2026 | Travere Therapeutics Inc. | Open-market sale | −2,600 | $63.50 | $165,100 |
| Aug 17, 2026 | Travere Therapeutics Inc. | Open-market sale | −500 | $64.16 | $32,080 |
| May 21, 2026 | Neurocrine Biosciences Inc. | Option exercise | +1,659 | — | — |
| May 19, 2026 | Travere Therapeutics Inc. | Grant or award | +4,000 | — | — |
| Apr 14, 2026 | Travere Therapeutics Inc. | Option exercise | +8,000 | $16.33 | $130,640 |
| Apr 14, 2026 | Travere Therapeutics Inc. | Open-market sale | −8,000 | $41.07 | $328,560 |
| Dec 3, 2025 | Neurocrine Biosciences Inc. | Option exercise | +15,000 | $47.89 | $718,350 |
| Dec 3, 2025 | Neurocrine Biosciences Inc. | Open-market sale | −15,000 | $152.61 | $2,289,150 |
| May 22, 2025 | Neurocrine Biosciences Inc. | Option exercise | +1,435 | — | — |
| May 15, 2025 | Travere Therapeutics Inc. | Grant or award | +6,500 | — | — |
Questions about Gary A. Lyons
What boards is Gary A. Lyons on?
Gary A. Lyons sits on the boards of Eledon Pharmaceuticals Inc., Neurocrine Biosciences Inc., Rigel Pharmaceuticals Inc. and Travere Therapeutics Inc.
How long has Gary A. Lyons served on boards?
Our records show at least 14 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.